Literature DB >> 11036832

Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities.

I N Bruce1, R J Burns, D D Gladman, M B Urowitz.   

Abstract

OBJECTIVE: To determine the prevalence of myocardial perfusion abnormalities in women with systemic lupus erythematosus (SLE) using single photon emission computed tomography (SPECT) dual isotope myocardial perfusion imaging (DIMPI).
METHODS: Consecutive female patients registered at the University of Toronto Lupus Clinic were offered DIMPI evaluation and all who accepted were studied. Patients underwent SPECT DIMPI using dipyridamole stress. Resting and stress images were acquired using thallium-201 (201TI) and technetium 99m-sestamibi (99mTc sestamibi), respectively. We recorded segmental perfusion abnormalities, severity and reversibility of any abnormality, and number of vessel territories involved. Ejection fraction was also measured.
RESULTS: One hundred thirty patients were studied. Mean (SD) age and disease duration at study were 45.1 (11.1) years and 14.6 (9.4) years, respectively. Thirteen patients (10%) had a history of angina pectoris or myocardial infarction. Overall, 52 (40%) patients had an abnormality of myocardial perfusion, including 11 (85%) with a history of angina or myocardial infarction. In those with no history of coronary artery disease, 41 (35%) had an abnormality detected. The perfusion defect was reversible in 47 (90%). In 37 (71%) cases perfusion defects were seen in the region of a single vessel territory. Eighteen (13.8%) patients had an ejection fraction (EF) < 50%.
CONCLUSION: Using SPECT DIMPI, 40% of all women with SLE and 35% of women with SLE with no history of coronary artery disease had abnormalities of myocardial perfusion, suggesting a high prevalence of early coronary artery disease. The early detection of disease will facilitate study of atherosclerotic risk factors; such women can also be targeted for a focused program of risk factor management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036832

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 2.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

Review 3.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

Review 4.  Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

Authors:  Allison B Reiss
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 5.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

Review 6.  Management of cardiovascular disease risk in chronic inflammatory disorders.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

Review 7.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

8.  Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.

Authors:  E M C Sella; E I Sato; W A Leite; J A Oliveira Filho; A Barbieri
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study.

Authors:  A Theodoridou; L Bento; D P D'Cruz; M A Khamashta; G R V Hughes
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

10.  Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Authors:  Emily C Somers; Wenpu Zhao; Emily E Lewis; Lu Wang; Jeffrey J Wing; Baskaran Sundaram; Ella A Kazerooni; W Joseph McCune; Mariana J Kaplan
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.